BCEIE › News › BPLPHARMA

Fund raising

Bharat Parenterals allots ₹139 crore preferential allotment

Bharat Parenterals (BPLPHARMA) said it has allotted preferential allotment of ₹139 crore. The company is valued at about ₹1,327 crore.

BCEIE News Desk · Published 29 Sept 2026, 04:39 pm IST · Filing received 29 Sept 2026, 04:22 pm IST

What happened

Bharat Parenterals (BPLPHARMA) told the exchanges on 29 September 2026 at 04:22 PM that it has allotted preferential allotment of ₹139 crore.

From the filing: "Convening of an Extraordinary general meeting on Friday, October 23, 2026 at 11:30 A.M through video conferencing or other audio-visual means, to seek necessary approval of the shareholders of the Company, for the Preferential Issue."

How big is it?

At ₹139 crore, the issue is equal to about 10.5% of the company's market value of ₹1,327 crore.

Company snapshot

Bharat Parenterals is a small-cap company, with a market value of about ₹1,327 crore.

The stock last traded at ₹1,926, against a 52-week range of ₹1,201.1–₹2,277.6 (15.4% below the high).

Before this filing the shares had moved +43.6% over the month. Average daily turnover over the last 20 sessions was about ₹2.26 crore.

Promoters held 67.20% at the end of Q1 FY27, up 0.03% points from the previous quarter. Foreign institutions owned 0.11% and domestic institutions 1.37%.

Quarterly results (standalone, ₹ crore)
QuarterRevenueNet profitEPS (₹)
Q1 FY26941014.51
Q2 FY26422.73.96
Q3 FY26411.92.78
Q4 FY26571.42
Q1 FY27563.75.31

What history shows

BCEIE has no earlier fund raising filing from this company on record since May 2026.

Market-wide, 1,465 fund raising filings with an impact score of 50 or more saw an average next-day move of +0.5%, with 49% rising.

Past reactions describe what happened before; they are not a forecast.

What to watch

  • How the money raised is used and, for equity instruments, the dilution for existing shareholders.

In the news

Recent coverage elsewhere (links open the original publisher):

Source

Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.